Cardiff Oncology Inc. (NASDAQ:CRDF) Relative Strength Index (RSI) is 37.21, with weekly volatility at 5.30% and ATR at 0.56. The CRDF stock’s 52-week price range has touched low of $2.23 and a $25.50 high. Intraday shares traded counted 0.51 million, which was 32.78% higher than its 30-day average trading volume of 754.12K. Its shares traded lower over the last trading session, losing -4.39% on 06/03/21. The shares fell to a low of $7.59 before closing at $7.63. CRDF’s previous close was $7.98 while the outstanding shares total 37.16M. The firm has a beta of 1.82.
Investors have identified the Biotechnology company Cardiff Oncology Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $284.14 million, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Cardiff Oncology Inc. (CRDF) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 128.57 million total, with 4.48 million as their total liabilities.
CRDF were able to record -5.88 million as free cash flow during the 07/30/2021 quarter of the year, this saw their quarterly net cash flow reduce by -116.32 million. In cash movements, the company had a total of -5.88 million as operating cash flow.
Potential earnings growth for Cardiff Oncology Inc. (CRDF)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the 07/30/2021 quarter of the year, Cardiff Oncology Inc. recorded a total of 72000.0 in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 5.56% coming in sequential stages and their sales for the 07/30/2021 quarter reducing by -65.28%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 72000.0 trying to sell their products during the last quarter, with the result yielding a gross income of 5.51 million. This allows shareholders to hold on to 37.16M with the recently reported earning now reading -0.14 cents per share. This is a figure that compared to analyst’s prediction for their 07/30/2021 (-0.14 cents a share).
Having a look at the company’s valuation, the company is expected to record -1.01 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on CRDF sounds very interesting.
Is the stock of CRDF attractive?
In related news, Director, Markin Rodney S bought 2,900 shares of the company’s stock in a transaction that recorded on Mar 26. The purchase was performed at an average price of 10.32, for a total value of 29,933. As the purchase deal closes, the Director, PACE GARY W now bought 10,000 shares of the company’s stock, valued at 102,300. Also, Director, JACOB GARY S bought 2,370 shares of the company’s stock in a deal that was recorded on Mar 23. The shares were cost at an average price of 10.42 per share, with a total market value of 24,689. Following this completion of disposal, the Exec. VP and COO, Kelemen Vicki now holds 960 shares of the company’s stock, valued at 9,898. In the last 6 months, insiders have changed their ownership in shares of company stock by 1.40%.